310 related articles for article (PubMed ID: 31335250)
21. Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation.
Baek DW; Kim J; Cho HJ; Moon JH; Sohn SK
Expert Rev Hematol; 2020 Sep; 13(9):959-969. PubMed ID: 32731765
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective.
Wu Y; Li Y; Gao Y; Zhang P; Jing Q; Zhang Y; Jin W; Wang Y; Du J; Wu G
Biomed Pharmacother; 2024 Feb; 171():116132. PubMed ID: 38198961
[TBL] [Abstract][Full Text] [Related]
24. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
25. Successful Transfer of Umbilical Cord Blood CD34
Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
[No Abstract] [Full Text] [Related]
26. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
27. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
28. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
30. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
[TBL] [Abstract][Full Text] [Related]
31. Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
Núñez-Torrón Stock C; Jiménez Chillón C; Martín Moro F; Marquet Palomanes J; Velázquez Kennedy K; Piris Villaespesa M; Roldán Santiago E; Rodríguez Martín E; Chinea Rodríguez A; García Gutiérrez V; Moreno Jiménez G; López Jiménez J; Herrera Puente P
Hematol Oncol; 2023 Oct; 41(4):753-761. PubMed ID: 37081742
[TBL] [Abstract][Full Text] [Related]
32. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Czyz A; Nagler A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
[TBL] [Abstract][Full Text] [Related]
33. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
Loren AW; Porter DL
Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
[TBL] [Abstract][Full Text] [Related]
35. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
[TBL] [Abstract][Full Text] [Related]
36. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
37. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
38. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
39. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
Kreidieh F; Abou Dalle I; Moukalled N; El-Cheikh J; Brissot E; Mohty M; Bazarbachi A
Int J Hematol; 2022 Sep; 116(3):330-340. PubMed ID: 35841458
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in acute myeloid leukemia.
Arpinati M; Curti A
Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
